These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35607747)

  • 1. Association of Frailty, Age, and Biological Sex With Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine-Induced Immunity in Older Adults.
    Shapiro JR; Sitaras I; Park HS; Aytenfisu TY; Caputo C; Li M; Lee J; Johnston TS; Li H; Wouters C; Hauk P; Jacobsen H; Li Y; Abrams E; Yoon S; Kocot AJ; Yang T; Huang Y; Cramer SM; Betenbaugh MJ; Debes AK; Morgan R; Milstone AM; Karaba AH; Pekosz A; Leng SX; Klein SL
    Clin Infect Dis; 2022 Aug; 75(Suppl 1):S61-S71. PubMed ID: 35607747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Older Adults Mount Less Durable Humoral Responses to Two Doses of COVID-19 mRNA Vaccine but Strong Initial Responses to a Third Dose.
    Mwimanzi F; Lapointe HR; Cheung PK; Sang Y; Yaseen F; Umviligihozo G; Kalikawe R; Datwani S; Omondi FH; Burns L; Young L; Leung V; Agafitei O; Ennis S; Dong W; Basra S; Lim LY; Ng K; Pantophlet R; Brumme CJ; Montaner JSG; Prystajecky N; Lowe CF; DeMarco ML; Holmes DT; Simons J; Niikura M; Romney MG; Brumme ZL; Brockman MA
    J Infect Dis; 2022 Sep; 226(6):983-994. PubMed ID: 35543278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Previous SARS-CoV-2 Infection, Age, and Frailty Are Associated With 6-Month Vaccine-Induced Anti-Spike Antibody Titer in Nursing Home Residents.
    Dyer AH; Noonan C; McElheron M; Batten I; Reddy C; Connolly E; Pierpoint R; Murray C; Leonard A; Higgins C; Reilly P; Boran G; Phelan T; McCormack W; O'Neill D; Fallon A; Brady G; O'Farrelly C; Bourke NM; Kennelly SP
    J Am Med Dir Assoc; 2022 Mar; 23(3):434-439. PubMed ID: 35219507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of Pfizer (BNT162b2) Vaccine-Induced Antibody Responses against the SARS-CoV-2 Omicron Variant in Adolescents and Adults.
    Gupta SL; Mantus G; Manning KE; Ellis M; Patel M; Ciric CR; Lu A; Turner JS; O'Halloran JA; Presti RM; Joshi DJ; Ellebedy AH; Anderson EJ; Rostad CA; Suthar MS; Wrammert J
    J Virol; 2022 Sep; 96(17):e0058222. PubMed ID: 35976000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing.
    O'Shea KM; Schuler CF; Chen J; Troost JP; Wong PT; Chen K; O'Shea DR; Peng W; Gherasim C; Manthei DM; Valdez R; Baldwin JL; Baker JR
    Front Immunol; 2023; 14():1055429. PubMed ID: 36845123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.
    Furukawa K; Tjan LH; Kurahashi Y; Sutandhio S; Nishimura M; Arii J; Mori Y
    JAMA Netw Open; 2022 May; 5(5):e2210780. PubMed ID: 35532938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects.
    Haveri A; Solastie A; Ekström N; Österlund P; Nohynek H; Nieminen T; Palmu AA; Melin M
    Eur J Immunol; 2022 May; 52(5):816-824. PubMed ID: 35312186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.
    Itamochi M; Yazawa S; Inasaki N; Saga Y; Yamazaki E; Shimada T; Tamura K; Maenishi E; Isobe J; Nakamura M; Takaoka M; Sasajima H; Kawashiri C; Tani H; Oishi K
    Vaccine; 2023 Mar; 41(13):2234-2242. PubMed ID: 36858871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses.
    Nam M; Yun SG; Kim SW; Kim CG; Cha JH; Lee C; Kang S; Park SG; Kim SB; Lee KB; Chung YS; Nam MH; Lee CK; Cho Y
    Microbiol Spectr; 2022 Aug; 10(4):e0249521. PubMed ID: 35946811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination.
    Graninger M; Camp JV; Aberle SW; Traugott MT; Hoepler W; Puchhammer-Stöckl E; Weseslindtner L; Zoufaly A; Aberle JH; Stiasny K
    Front Immunol; 2022; 13():888794. PubMed ID: 35711424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-Related Differences in Neutralizing Antibody Responses against SARS-CoV-2 Delta and Omicron Variants in 151 SARS-CoV-2-Naïve Metropolitan Residents Boosted with BNT162b2.
    Lee B; Bae GE; Jeong IH; Kim JH; Kwon MJ; Kim J; Kim B; Lee JW; Nam JH; Huh HJ; Kang ES
    J Appl Lab Med; 2024 Jul; 9(4):741-751. PubMed ID: 38531067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
    Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L
    Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History.
    Drews SJ; Hu Q; Samson R; Abe KT; Rathod B; Colwill K; Gingras AC; Yi QL; O'Brien SF
    Microbiol Spectr; 2022 Feb; 10(1):e0226221. PubMed ID: 35171006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
    Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
    J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial.
    Poh XY; Tan CW; Lee IR; Chavatte JM; Fong SW; Prince T; Hartley C; Yeoh AYY; Rao S; Chia PY; Ong SWX; Lee TH; Sadarangani SP; Lin RJH; Lim C; Teo J; Lim DRX; Chia W; Hiscox JA; Ng LFP; Ren EC; Lin RTP; Renia L; Lye DC; Wang LF; Young BE
    Clin Infect Dis; 2022 Dec; 75(12):2088-2096. PubMed ID: 35543372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant.
    Valanparambil RM; Carlisle J; Linderman SL; Akthar A; Millett RL; Lai L; Chang A; McCook-Veal AA; Switchenko J; Nasti TH; Saini M; Wieland A; Manning KE; Ellis M; Moore KM; Foster SL; Floyd K; Davis-Gardner ME; Edara VV; Patel M; Steur C; Nooka AK; Green F; Johns MA; O'Brein F; Shanmugasundaram U; Zarnitsyna VI; Ahmed H; Nyhoff LE; Mantus G; Garett M; Edupuganti S; Behra M; Antia R; Wrammert J; Suthar MS; Dhodapkar MV; Ramalingam S; Ahmed R
    J Clin Oncol; 2022 Nov; 40(33):3808-3816. PubMed ID: 35759727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mRNA vaccine boosting enhances antibody responses against SARS-CoV-2 Omicron variant in individuals with antibody deficiency syndromes.
    Zimmerman O; Altman Doss AM; Kaplonek P; Liang CY; VanBlargan LA; Chen RE; Monroy JM; Wedner HJ; Kulczycki A; Mantia TL; O'Shaughnessy CC; Davis-Adams HG; Bertera HL; Adams LJ; Raju S; Zhao FR; Rigell CJ; Dy TB; Kau AL; Ren Z; Turner JS; O'Halloran JA; Presti RM; Fremont DH; Kendall PL; Ellebedy AH; Alter G; Diamond MS
    Cell Rep Med; 2022 Jun; 3(6):100653. PubMed ID: 35688161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine.
    Mwimanzi F; Lapointe HR; Cheung PK; Sang Y; Yaseen F; Kalikawe R; Datwani S; Burns L; Young L; Leung V; Ennis S; Brumme CJ; Montaner JSG; Dong W; Prystajecky N; Lowe CF; DeMarco ML; Holmes DT; Simons J; Niikura M; Romney MG; Brumme ZL; Brockman MA
    Open Forum Infect Dis; 2023 Mar; 10(3):ofad073. PubMed ID: 36910697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.